Learn about our comprehensive antibody validation methods to ensure monospecificity.  Antibody Validation>>

Primary Antibodies

Discover your next breakthrough.

NeoBiotechnologies’ primary antibodies enable researchers and pathologists to investigate the functions, interactions, and expression patterns of target proteins within the human proteome.

Primary antibodies play a crucial role in scientific research and diagnostics, including cancer research. As the cornerstone of NeoBiotechnologies’ product offerings, primary antibodies are highly specific proteins that recognize and bind to target antigens, which are often proteins of interest. By targeting specific proteins within the human proteome, NeoBiotechnologies’ primary antibodies enable researchers and pathologists to investigate the functions, interactions, and expression patterns of these proteins.

With NeoBiotechnologies’ primary antibodies, scientists can delve into various applications, such as immunohistochemistry (IHC), immunofluorescence (IF), Western blotting (WB), enzyme-linked immunosorbent assays (ELISA), and flow cytometry. These antibodies serve as powerful tools for studying disease mechanisms, identifying potential therapeutic targets, and enhancing diagnostic accuracy.

Decorin Antibody in Immunohistochemistry (IHC (P))

By providing a comprehensive collection of primary antibodies that cover the entire human proteome, NeoBiotechnologies empowers scientists, pathologists, and biomedical professionals to uncover new insights, accelerate discoveries, and ultimately contribute to improved patient care and outcomes in the fight against cancer.

NeoBiotechnologies’ antibodies are tested on the HuProt Protein Array, containing >21,000 full-length proteins on a slide. By using this standardized and comprehensive platform, we are able to assess antibody specificity, epitope mapping, binding affinity, reproducibility, and optimize antibody design. Our HuProt Array enables reliable and thorough antibody validation, ensuring the utmost confidence in the performance and suitability of our antibodies for cutting-edge research and diagnostic applications.

PARTNERSHIP OPPORTUNITIES

We hold Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.

LETS TALK